Brain Imaging Modalities Market by Modality (Computed Tomography, Magnetic Resonance Imaging, Optical Imaging), Patient Type (Adults, Pediatrics, Infants), Application, End User - Global Forecast 2025-2032
Description
The Brain Imaging Modalities Market was valued at USD 13.99 billion in 2024 and is projected to grow to USD 15.37 billion in 2025, with a CAGR of 10.47%, reaching USD 31.04 billion by 2032.
An authoritative introduction to how advances in acquisition, analytics, and care delivery are redefining clinical and research applications of brain imaging
Brain imaging occupies a pivotal role at the intersection of clinical care, neuroscience research, and digital health innovation. Advances in acquisition hardware, signal processing, and multimodal integration have expanded what clinicians and investigators can observe about brain structure, function, and pathology. These technical developments are enabling earlier detection of neurodegenerative conditions, more precise mapping of epileptogenic zones, and more robust monitoring of therapeutic response in clinical trials and practice.
Alongside technical progress, changing care models and increased demand for outpatient diagnostics have accelerated deployment in ambulatory care facilities and diagnostic centers, while academic institutions and research institutes continue to drive fundamental discovery. The discipline now balances high-resolution anatomical imaging, physiologic and metabolic assessments, and portable, point-of-care modalities. As stakeholders evaluate investment and adoption strategies, they must weigh device capabilities, workflow integration, data interoperability, and regulatory compliance to translate advances into improved patient outcomes.
How converging advances in hybrid instrumentation, algorithmic analytics, and decentralized care models are reshaping clinical pathways and procurement priorities in brain imaging
The brain imaging landscape is undergoing transformative shifts driven by converging technological, clinical, and policy trends. On the technology front, improvements in detector sensitivity, pulse-sequence design, and hybrid imaging architectures are narrowing the gap between structural and functional information, enabling richer multimodal datasets that inform both diagnostics and therapeutic planning. Concurrently, artificial intelligence and advanced analytics are maturing from research prototypes into regulated components that enhance image reconstruction, lesion detection, and quantitative biomarkers, changing diagnostic workflows and vendor value propositions.
Clinically, there is a clear movement toward precision diagnostics and personalized monitoring, with imaging increasingly used to stratify patients for targeted therapies and to serve as surrogate endpoints in trials. Operationally, the decentralization of care, the growth of outpatient imaging, and the need for rapid, reproducible results are pressuring manufacturers to deliver streamlined user experiences and robust interoperability. Taken together, these shifts are reshaping procurement criteria, clinical pathways, and research priorities across institutions that rely on brain imaging.
Evaluating the operational and strategic repercussions of United States tariff measures introduced in 2025 on sourcing, procurement, and research continuity in brain imaging
Recent trade measures and tariff adjustments enacted in 2025 have introduced new variables into supply chain planning, procurement cycles, and international collaboration within the brain imaging ecosystem. For medical device manufacturers, higher levies on imported components and finished systems influence sourcing strategies, leading many to reassess supplier footprints and accelerate localization of key subsystems where feasible. As a result, procurement teams and hospital administrators must balance potential cost inflation with considerations of lead time, warranty coverage, and long-term support commitments.
Academic institutions and research institutes that depend on cross-border collaboration face heightened complexity when shipping sensitive equipment or radioactive tracers for positron emission studies, which can disrupt experimental timelines and grant-driven milestones. Diagnostic centers and ambulatory facilities may encounter adjusted pricing structures and extended delivery windows that affect capital planning. To mitigate operational risk, stakeholders are revisiting contract terms, exploring multi-sourcing strategies, and emphasizing modular upgrades that reduce dependence on new-capital procurement during periods of tariff-induced uncertainty.
Deep segmentation analysis revealing modality-specific subtypes, application-driven demand vectors, and end-user workflows that determine adoption dynamics and clinical evidence requirements
A granular understanding of modality, application, and end-user segmentation reveals where value creation and adoption momentum concentrate across the brain imaging landscape. Based on modality, market studies examine Computed Tomography alongside Magnetic Resonance Imaging, Optical Imaging, Positron Emission Tomography, Single Photon Emission Computer Tomography, and Ultrasound Imaging, with Computed Tomography subdivided into Cone Beam and Conventional configurations and Magnetic Resonance Imaging further differentiated by Angiography, Diffusion, Functional, and Structural techniques. Optical Imaging is explored through functional near-infrared spectroscopy and Optical Coherence Tomography modalities, Positron Emission Tomography divides into Amyloid, Dopamine, and FDG tracers, Single Photon Emission Computer Tomography focuses on Dopamine Transporter applications, and Ultrasound Imaging considers Biomicroscopy and Transcranial Doppler approaches.
From an application perspective, distinctions among Diagnostics, Research, and Therapeutic Monitoring illuminate demand drivers and evidence requirements. The Diagnostics axis includes the evaluation of Epilepsy, Neurodegenerative Disorders, Traumatic Brain Injury, Tumor Detection, and Vascular Disease, while Research spans Brain Mapping, Neuroscience, and Pharmaceutical Development with Neuroscience delineated into Basic Research and Clinical Research activities. Therapeutic Monitoring emphasizes Disease Progression Tracking, Surgical Monitoring, and Treatment Response Assessment. Considering end-user segmentation, stakeholders range from Academic Institutions and Ambulatory Care Facilities to Diagnostic Centers, Home Healthcare, Hospitals, and Research Institutes, with Academic Institutions encompassing Medical Schools and Universities and Research Institutes comprising Government Labs and Private Labs. These layered segmentations underscore the need for differentiated product features, data governance models, and service arrangements tailored to modality-specific workflows and the distinct regulatory and operational contexts of each end user.
Comparative regional perspectives revealing how reimbursement, clinical networks, and infrastructure investment patterns influence modality adoption across global markets
Regional dynamics shape adoption patterns, reimbursement frameworks, and innovation partnerships across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, academic medical centers, integrated delivery networks, and private imaging providers drive demand for advanced MRI protocols, hybrid PET/MR capabilities, and scalable CT solutions optimized for throughput. Regulatory pathways and reimbursement models in this region encourage rapid clinical translation when comparative effectiveness and patient outcome data are compelling.
Europe, the Middle East & Africa present diverse regulatory landscapes and a mix of public and private healthcare delivery that influence procurement timelines and the prioritization of interoperable platforms. Collaborative research consortia and pan-national clinical studies contribute to adoption of standardized imaging protocols, while resource variability across countries emphasizes modular and cost-effective solutions. The Asia-Pacific region is characterized by substantial investment in imaging infrastructure, a growing clinician base trained on advanced modalities, and an emphasis on point-of-care and portable imaging to extend access. Cross-border manufacturing and regional supply hubs also play important roles in how manufacturers structure service networks and localization strategies.
Insights into competitive positioning and partnership models that determine vendor success and influence customer selection criteria across the brain imaging ecosystem
Competitive dynamics in brain imaging reflect a blend of established multinational manufacturers, specialized modality-focused firms, and agile technology entrants that emphasize software-driven differentiation. Leading equipment providers maintain broad portfolios across CT and MRI and continue to invest in higher-field systems, advanced coil design, and workflow automation to preserve clinical trust and service ecosystems. Simultaneously, niche vendors concentrate on targeted applications such as optical imaging systems, portable ultrasound transcranial solutions, and tracer-specific PET technologies, enabling them to partner with academic centers for validation and early clinical adoption.
Software and analytics companies are accelerating validation of image reconstruction algorithms, lesion segmentation tools, and quantitative biomarker extraction pipelines that integrate into vendor-neutral archives and picture archiving and communication systems. Strategic partnerships between hardware vendors and analytics providers are increasing, reflecting a shift toward bundled solutions that reduce integration friction for hospitals and research institutes. For customers, supplier selection increasingly hinges on lifecycle service offerings, modular upgrade paths, regulatory compliance of AI components, and demonstrable clinical utility in prioritized applications such as neurodegenerative disorder assessment and perioperative monitoring.
Actionable strategic priorities for vendors and healthcare leaders to drive adoption through interoperability, robust real-world evidence, and adaptable commercial models
Industry leaders should prioritize interoperability, evidence generation, and flexible deployment models to sustain growth and clinical relevance. First, invest in open standards and interoperable data formats to ensure seamless integration into electronic health records, research databases, and cross-vendor archives; this reduces implementation friction and supports multicenter research collaborations. Second, accelerate clinical validation programs that demonstrate diagnostic utility and longitudinal monitoring capability across prioritized applications such as neurodegenerative disorders and epileptology, because payers and procurement teams increasingly demand robust real-world evidence.
Third, redesign commercial models to offer modular upgrades, subscription-based analytic services, and field-upgradable hardware options that reduce initial capital barriers and align vendor incentives with long-term outcomes. Fourth, diversify supply chains and consider regional manufacturing or assembly to mitigate tariff exposure and shorten lead times, while maintaining quality control and regulatory compliance. Finally, invest in clinician education and workflow redesign programs that lower the cognitive and operational barriers to adoption, ensuring that technological gains translate into measurable improvements in care delivery and research throughput.
A rigorous multi-source methodology combining stakeholder interviews, technical assessments, and validation workshops to ensure credible and actionable insights
The research methodology underpinning this report combines primary stakeholder engagement, secondary literature synthesis, and structured validation to ensure rigor and relevance. Primary inputs include interviews with clinicians, imaging scientists, procurement officers, and research directors across academic institutions, hospitals, ambulatory care settings, and diagnostic centers to capture first-hand perspectives on clinical needs, operational constraints, and procurement drivers. These qualitative insights are triangulated with peer-reviewed literature, regulatory guidance documents, clinical trial protocols, and technical standards to contextualize findings and highlight consensus areas.
Analytical steps incorporate modality-specific technology assessments, application evidence mapping, and end-user workflow analyses to identify capability gaps and adoption barriers. Scenario analyses examine supply-chain stressors and policy changes, while vendor landscape mapping assesses product features, service models, and partnership ecosystems. Throughout the process, validation workshops with subject-matter experts refine assumptions and ensure that conclusions reflect practical realities within clinical and research environments.
Concluding synthesis highlighting the integration of technology, evidence generation, and operational resilience as the pathway to realizing the clinical and research potential of brain imaging
In summary, brain imaging is transitioning from discrete modality silos toward an integrated ecosystem where hybrid instrumentation, algorithmic analytics, and service-oriented commercial models converge to support precision diagnostics and monitoring. Stakeholders must navigate evolving regulatory expectations for algorithmic tools, shifting procurement priorities driven by care decentralization, and operational uncertainties introduced by trade policy changes. Institutions that align technology selection with interoperable data strategies, robust clinical validation efforts, and adaptable commercial agreements will better translate imaging advances into improved patient care and research productivity.
Looking ahead, collaboration among device manufacturers, software vendors, academic centers, and payers will be essential to standardize quantitative biomarkers, scale validation across diverse populations, and create outcomes-based purchasing frameworks. By focusing on implementable evidence, supply chain resilience, and clinician-centered design, industry participants can unlock the full clinical and research value of modern brain imaging capabilities.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction to how advances in acquisition, analytics, and care delivery are redefining clinical and research applications of brain imaging
Brain imaging occupies a pivotal role at the intersection of clinical care, neuroscience research, and digital health innovation. Advances in acquisition hardware, signal processing, and multimodal integration have expanded what clinicians and investigators can observe about brain structure, function, and pathology. These technical developments are enabling earlier detection of neurodegenerative conditions, more precise mapping of epileptogenic zones, and more robust monitoring of therapeutic response in clinical trials and practice.
Alongside technical progress, changing care models and increased demand for outpatient diagnostics have accelerated deployment in ambulatory care facilities and diagnostic centers, while academic institutions and research institutes continue to drive fundamental discovery. The discipline now balances high-resolution anatomical imaging, physiologic and metabolic assessments, and portable, point-of-care modalities. As stakeholders evaluate investment and adoption strategies, they must weigh device capabilities, workflow integration, data interoperability, and regulatory compliance to translate advances into improved patient outcomes.
How converging advances in hybrid instrumentation, algorithmic analytics, and decentralized care models are reshaping clinical pathways and procurement priorities in brain imaging
The brain imaging landscape is undergoing transformative shifts driven by converging technological, clinical, and policy trends. On the technology front, improvements in detector sensitivity, pulse-sequence design, and hybrid imaging architectures are narrowing the gap between structural and functional information, enabling richer multimodal datasets that inform both diagnostics and therapeutic planning. Concurrently, artificial intelligence and advanced analytics are maturing from research prototypes into regulated components that enhance image reconstruction, lesion detection, and quantitative biomarkers, changing diagnostic workflows and vendor value propositions.
Clinically, there is a clear movement toward precision diagnostics and personalized monitoring, with imaging increasingly used to stratify patients for targeted therapies and to serve as surrogate endpoints in trials. Operationally, the decentralization of care, the growth of outpatient imaging, and the need for rapid, reproducible results are pressuring manufacturers to deliver streamlined user experiences and robust interoperability. Taken together, these shifts are reshaping procurement criteria, clinical pathways, and research priorities across institutions that rely on brain imaging.
Evaluating the operational and strategic repercussions of United States tariff measures introduced in 2025 on sourcing, procurement, and research continuity in brain imaging
Recent trade measures and tariff adjustments enacted in 2025 have introduced new variables into supply chain planning, procurement cycles, and international collaboration within the brain imaging ecosystem. For medical device manufacturers, higher levies on imported components and finished systems influence sourcing strategies, leading many to reassess supplier footprints and accelerate localization of key subsystems where feasible. As a result, procurement teams and hospital administrators must balance potential cost inflation with considerations of lead time, warranty coverage, and long-term support commitments.
Academic institutions and research institutes that depend on cross-border collaboration face heightened complexity when shipping sensitive equipment or radioactive tracers for positron emission studies, which can disrupt experimental timelines and grant-driven milestones. Diagnostic centers and ambulatory facilities may encounter adjusted pricing structures and extended delivery windows that affect capital planning. To mitigate operational risk, stakeholders are revisiting contract terms, exploring multi-sourcing strategies, and emphasizing modular upgrades that reduce dependence on new-capital procurement during periods of tariff-induced uncertainty.
Deep segmentation analysis revealing modality-specific subtypes, application-driven demand vectors, and end-user workflows that determine adoption dynamics and clinical evidence requirements
A granular understanding of modality, application, and end-user segmentation reveals where value creation and adoption momentum concentrate across the brain imaging landscape. Based on modality, market studies examine Computed Tomography alongside Magnetic Resonance Imaging, Optical Imaging, Positron Emission Tomography, Single Photon Emission Computer Tomography, and Ultrasound Imaging, with Computed Tomography subdivided into Cone Beam and Conventional configurations and Magnetic Resonance Imaging further differentiated by Angiography, Diffusion, Functional, and Structural techniques. Optical Imaging is explored through functional near-infrared spectroscopy and Optical Coherence Tomography modalities, Positron Emission Tomography divides into Amyloid, Dopamine, and FDG tracers, Single Photon Emission Computer Tomography focuses on Dopamine Transporter applications, and Ultrasound Imaging considers Biomicroscopy and Transcranial Doppler approaches.
From an application perspective, distinctions among Diagnostics, Research, and Therapeutic Monitoring illuminate demand drivers and evidence requirements. The Diagnostics axis includes the evaluation of Epilepsy, Neurodegenerative Disorders, Traumatic Brain Injury, Tumor Detection, and Vascular Disease, while Research spans Brain Mapping, Neuroscience, and Pharmaceutical Development with Neuroscience delineated into Basic Research and Clinical Research activities. Therapeutic Monitoring emphasizes Disease Progression Tracking, Surgical Monitoring, and Treatment Response Assessment. Considering end-user segmentation, stakeholders range from Academic Institutions and Ambulatory Care Facilities to Diagnostic Centers, Home Healthcare, Hospitals, and Research Institutes, with Academic Institutions encompassing Medical Schools and Universities and Research Institutes comprising Government Labs and Private Labs. These layered segmentations underscore the need for differentiated product features, data governance models, and service arrangements tailored to modality-specific workflows and the distinct regulatory and operational contexts of each end user.
Comparative regional perspectives revealing how reimbursement, clinical networks, and infrastructure investment patterns influence modality adoption across global markets
Regional dynamics shape adoption patterns, reimbursement frameworks, and innovation partnerships across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, academic medical centers, integrated delivery networks, and private imaging providers drive demand for advanced MRI protocols, hybrid PET/MR capabilities, and scalable CT solutions optimized for throughput. Regulatory pathways and reimbursement models in this region encourage rapid clinical translation when comparative effectiveness and patient outcome data are compelling.
Europe, the Middle East & Africa present diverse regulatory landscapes and a mix of public and private healthcare delivery that influence procurement timelines and the prioritization of interoperable platforms. Collaborative research consortia and pan-national clinical studies contribute to adoption of standardized imaging protocols, while resource variability across countries emphasizes modular and cost-effective solutions. The Asia-Pacific region is characterized by substantial investment in imaging infrastructure, a growing clinician base trained on advanced modalities, and an emphasis on point-of-care and portable imaging to extend access. Cross-border manufacturing and regional supply hubs also play important roles in how manufacturers structure service networks and localization strategies.
Insights into competitive positioning and partnership models that determine vendor success and influence customer selection criteria across the brain imaging ecosystem
Competitive dynamics in brain imaging reflect a blend of established multinational manufacturers, specialized modality-focused firms, and agile technology entrants that emphasize software-driven differentiation. Leading equipment providers maintain broad portfolios across CT and MRI and continue to invest in higher-field systems, advanced coil design, and workflow automation to preserve clinical trust and service ecosystems. Simultaneously, niche vendors concentrate on targeted applications such as optical imaging systems, portable ultrasound transcranial solutions, and tracer-specific PET technologies, enabling them to partner with academic centers for validation and early clinical adoption.
Software and analytics companies are accelerating validation of image reconstruction algorithms, lesion segmentation tools, and quantitative biomarker extraction pipelines that integrate into vendor-neutral archives and picture archiving and communication systems. Strategic partnerships between hardware vendors and analytics providers are increasing, reflecting a shift toward bundled solutions that reduce integration friction for hospitals and research institutes. For customers, supplier selection increasingly hinges on lifecycle service offerings, modular upgrade paths, regulatory compliance of AI components, and demonstrable clinical utility in prioritized applications such as neurodegenerative disorder assessment and perioperative monitoring.
Actionable strategic priorities for vendors and healthcare leaders to drive adoption through interoperability, robust real-world evidence, and adaptable commercial models
Industry leaders should prioritize interoperability, evidence generation, and flexible deployment models to sustain growth and clinical relevance. First, invest in open standards and interoperable data formats to ensure seamless integration into electronic health records, research databases, and cross-vendor archives; this reduces implementation friction and supports multicenter research collaborations. Second, accelerate clinical validation programs that demonstrate diagnostic utility and longitudinal monitoring capability across prioritized applications such as neurodegenerative disorders and epileptology, because payers and procurement teams increasingly demand robust real-world evidence.
Third, redesign commercial models to offer modular upgrades, subscription-based analytic services, and field-upgradable hardware options that reduce initial capital barriers and align vendor incentives with long-term outcomes. Fourth, diversify supply chains and consider regional manufacturing or assembly to mitigate tariff exposure and shorten lead times, while maintaining quality control and regulatory compliance. Finally, invest in clinician education and workflow redesign programs that lower the cognitive and operational barriers to adoption, ensuring that technological gains translate into measurable improvements in care delivery and research throughput.
A rigorous multi-source methodology combining stakeholder interviews, technical assessments, and validation workshops to ensure credible and actionable insights
The research methodology underpinning this report combines primary stakeholder engagement, secondary literature synthesis, and structured validation to ensure rigor and relevance. Primary inputs include interviews with clinicians, imaging scientists, procurement officers, and research directors across academic institutions, hospitals, ambulatory care settings, and diagnostic centers to capture first-hand perspectives on clinical needs, operational constraints, and procurement drivers. These qualitative insights are triangulated with peer-reviewed literature, regulatory guidance documents, clinical trial protocols, and technical standards to contextualize findings and highlight consensus areas.
Analytical steps incorporate modality-specific technology assessments, application evidence mapping, and end-user workflow analyses to identify capability gaps and adoption barriers. Scenario analyses examine supply-chain stressors and policy changes, while vendor landscape mapping assesses product features, service models, and partnership ecosystems. Throughout the process, validation workshops with subject-matter experts refine assumptions and ensure that conclusions reflect practical realities within clinical and research environments.
Concluding synthesis highlighting the integration of technology, evidence generation, and operational resilience as the pathway to realizing the clinical and research potential of brain imaging
In summary, brain imaging is transitioning from discrete modality silos toward an integrated ecosystem where hybrid instrumentation, algorithmic analytics, and service-oriented commercial models converge to support precision diagnostics and monitoring. Stakeholders must navigate evolving regulatory expectations for algorithmic tools, shifting procurement priorities driven by care decentralization, and operational uncertainties introduced by trade policy changes. Institutions that align technology selection with interoperable data strategies, robust clinical validation efforts, and adaptable commercial agreements will better translate imaging advances into improved patient care and research productivity.
Looking ahead, collaboration among device manufacturers, software vendors, academic centers, and payers will be essential to standardize quantitative biomarkers, scale validation across diverse populations, and create outcomes-based purchasing frameworks. By focusing on implementable evidence, supply chain resilience, and clinician-centered design, industry participants can unlock the full clinical and research value of modern brain imaging capabilities.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of ultra-high-field 7T and 11.7T MRI scanners enabling unprecedented brain resolution
- 5.2. Integration of artificial intelligence and deep learning algorithms for advanced neuroimaging analysis
- 5.3. Development of hybrid PET/MRI and SPECT/CT systems for comprehensive functional and structural mapping
- 5.4. Expansion of portable and point-of-care EEG and fNIRS devices for real-time neurological monitoring
- 5.5. Growing use of quantitative imaging biomarkers to assess neurodegenerative disease progression
- 5.6. Advancements in MR-guided focused ultrasound for non-invasive neuromodulation and targeted therapy
- 5.7. Adoption of cloud-based platforms and telemedicine solutions for remote brain imaging consultation
- 5.8. Innovation in radiopharmaceuticals and tracers for more specific molecular brain imaging diagnostics
- 5.9. Implementation of motion correction and accelerated imaging techniques to reduce scan time artifacts
- 5.10. Increased demand for functional connectivity mapping in psychiatric and cognitive disorder research
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Brain Imaging Modalities Market, by Modality
- 8.1. Computed Tomography
- 8.1.1. Cone Beam
- 8.1.2. Conventional
- 8.2. Magnetic Resonance Imaging
- 8.2.1. Angiography
- 8.2.2. Diffusion
- 8.2.3. Functional
- 8.2.4. Structural
- 8.3. Optical Imaging
- 8.3.1. Fnirs
- 8.3.2. Optical Coherence Tomography
- 8.4. Positron Emission Tomography
- 8.4.1. Amyloid
- 8.4.2. Dopamine
- 8.4.3. Fdg
- 8.5. Single Photon Emission Computer Tomography
- 8.6. Ultrasound Imaging
- 8.6.1. Biomicroscopy
- 8.6.2. Transcranial Doppler
- 9. Brain Imaging Modalities Market, by Patient Type
- 9.1. Adults
- 9.2. Pediatrics
- 9.3. Infants
- 10. Brain Imaging Modalities Market, by Application
- 10.1. Diagnostics
- 10.1.1. Epilepsy
- 10.1.2. Neurodegenerative Disorders
- 10.1.3. Traumatic Brain Injury
- 10.1.4. Tumor Detection
- 10.1.5. Vascular Disease
- 10.2. Research
- 10.2.1. Brain Mapping
- 10.2.2. Neuroscience
- 10.2.2.1. Basic Research
- 10.2.2.2. Clinical Research
- 10.2.3. Pharmaceutical Development
- 10.3. Therapeutic Monitoring
- 10.3.1. Disease Progression Tracking
- 10.3.2. Surgical Monitoring
- 10.3.3. Treatment Response Assessment
- 11. Brain Imaging Modalities Market, by End User
- 11.1. Academic Institutions
- 11.1.1. Medical Schools
- 11.1.2. Universities
- 11.2. Ambulatory Care Facilities
- 11.3. Diagnostic Centers
- 11.4. Home Healthcare
- 11.5. Hospitals
- 11.6. Research Institutes
- 11.6.1. Government Labs
- 11.6.2. Private Labs
- 12. Brain Imaging Modalities Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Brain Imaging Modalities Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Brain Imaging Modalities Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Advantis Medical Imaging
- 15.3.3. AiM Medical Robotics
- 15.3.4. Boston Scientific Corporation
- 15.3.5. Bruker Corporation
- 15.3.6. Canon Medical Systems Corporation
- 15.3.7. Elekta AB
- 15.3.8. EMVision Medical Devices Ltd.
- 15.3.9. Esaote SpA
- 15.3.10. Fujifilm Holdings Corporation
- 15.3.11. GE HealthCare Technologies, Inc.
- 15.3.12. Hitachi, Ltd.
- 15.3.13. Hologic, Inc.
- 15.3.14. Hyperfine Research, Inc.
- 15.3.15. Magnetic Insight, Inc.
- 15.3.16. Medtronic PLC
- 15.3.17. Octave Biosciences
- 15.3.18. Promaxo, Inc.
- 15.3.19. Royal Philips
- 15.3.20. Shimadzu Corporation
- 15.3.21. Siemens AG
- 15.3.22. Thermo Fisher Scientific Inc.
- 15.3.23. Toshiba Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
